First-in-man clinical study of SCMod1 [Modi-1 / AMPLIVANT combination] for cancer
Latest Information Update: 20 Apr 2022
At a glance
- Drugs Modi-1 (Primary) ; Antineoplastics
- Indications Breast cancer; Endometrial cancer; Head and neck cancer; Osteosarcoma; Ovarian cancer; Renal cancer; Sarcoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- 14 Apr 2022 Status changed from planning to recruiting, according to an ISA Pharmaceuticals media release.
- 10 May 2019 According to a Scancell media release, the company expects to initiate this study in Q1 2020.
- 10 May 2019 According to a Scancell media release, the company has appointed six world-leading clinicians to establish a Clinical Advisory Board (CAB) which will guidance and support Moditope, to enter into clinic in multiple tumour types, including head and neck, breast and ovarian cancer.